Phase IV ELIOS Trial: Eye Movement Biomarkers to Track Ofatumumab Response in Multiple Sclerosis — What Clinicians Need to Know

References

1. 1.Comabella, M., & Montalban, X. (2014). Body fluid biomarkers in multiple sclerosis. Lancet Neurology, 13(1), 113-126. https://doi.org/10.1016/S1474-4422(14)70233-3
2. 2.Fielding, J., Kilpatrick, T., Millist, L., & White, O. (2009). Control of visually guided saccades in multiple sclerosis: disruption to higher-order processes. Neuropsychologia, 47(5), 1406-1415. https://doi.org/10.1016/j.neuropsychologia.2009.01.040
3. 3.Frohman, E. M., Frohman, T. C., Zee, D. S., McColl, R., & Galetta, S. (2005). The neuro-ophthalmology of multiple sclerosis. Lancet Neurology, 4(2), 111-121. https://doi.org/10.1016/S1474-4422(05)70270-2
4. 4.Hauser, S. L., Bar-Or, A., Cohen, J. A., Comi, G., Correale, J., Coyle, P. K., Cross, A. H., de Seze, J., Leppert, D., Montalban, X., Selmaj, K., Wiendl, H., Kerloeguen, C., Willi, R., Li, B., Kakarieka, A., Tomic, D., Goodyear, A., Pingili, R., ... Kappos, L. (2020). Ofatumumab versus teriflunomide in multiple sclerosis. New England Journal of Medicine, 383(6), 546-557. https://doi.org/10.1056/NEJMoa1917246
5. 5.Kobelt, G., Thompson, A., Berg, J., Gannedahl, M., Eriksson, J., & MSCOI Study Group. (2017). New insights into the burden and costs of multiple sclerosis in Europe. Multiple Sclerosis Journal, 23(8), 1123-1136. https://doi.org/10.1177/1352458517694432
6. 6.Novartis Pharmaceuticals. (2024). Exploratory Evaluation of Novel Investigational Eye Movement Biomarkers to Track Ofatumumab Treatment Response in Canadian Patients With Active Relapsing-Remitting Multiple Sclerosis (ELIOS). ClinicalTrials.gov. NCT06733922. https://clinicaltrials.gov/study/NCT06733922